Adherence: Discontinuations · people with transfusion‐dependent thalassemia
1 finding from 1 review
Adherence: Discontinuations · people with non‐transfusion‐dependent thalassemia
Deferasirox showed no clear difference in adherence: Discontinuations compared with placebo (low certainty).
1 finding from 1 review
Adherence: Discontinuations · people with transfusion‐dependent thalassemia
Deferasirox showed no clear difference in adherence: discontinuations compared with deferoxamine (low certainty).
1 finding from 1 review
Adverse events: Serious event or requiring discontinuation · schizophrenia or related disorders
It is very uncertain whether combinations of antipsychotic drugs changes adverse events: Serious event or requiring discontinuation compared with single antipsychotic drugs (very low certainty).
1 finding from 1 review
Intervention not reported
Discontinuation of treatment due to side effects ( · people with or at risk of cardiovascular disease
The intervention probably leads to higher discontinuation of treatment due to side effects ( (moderate certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · patients with relapsing‐remitting multiple sclerosis
It is very uncertain whether alemtuzumab 24 mg changes number of participants experiencing treatment discontinuation caused… compared with interferon beta 1a (very low certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 12 mg may leads to lower number of participants experiencing treatment discontinuation caused… compared with interferon beta 1a (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · anaemia in predialysis patients
Epoetin theta showed no clear difference in adverse events: discontinuation of therapy compared with epoetin beta (low certainty).
1 finding from 1 review
Discontinuation of therapy due to adverse events ‐ not measured · patients with non‐muscle invasive bladder cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Discontinuation of medication due to adverse events · patients with non‐muscle invasive bladder cancer
Intravesically administered BCG alternating with IFN‐α showed no clear difference in discontinuation of therapy due to adverse events compared with intravesically administered BCG alone (low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events
It is very uncertain whether are disease‐modifying drugs for a first attack suggestive of… changes withdrawls or drug discontinuation due to adverse events during 24… compared with placebo? (very low certainty).
1 finding from 1 review
OR 2.43 [0.91, 6.49]
Studies not reported
Very low
Discontinuation of medication due to adverse events · older people with normal cognitiona
Statins showed no clear difference in adverse events leading to discontinuation of therapy compared with placebo (high certainty).
1 finding from 1 review
Intervention not reported
Discontinuation rate · antiretroviral‐naïve individuals
The intervention showed no clear difference in discontinuation rate (moderate certainty).
1 finding from 1 review
Intervention not reported
Number of adverse events requiring discontinuation of treatment ‐ not reported · treating infections in people with neutropenia or neutrophil dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Discontinuation of therapy due to adverse effects · patients in primary prevention of cardiovascular disease events
It is very uncertain whether the intervention changes discontinuation of therapy due to adverse effects (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events leading to discontinuation of therapy · treating pulmonary TB
The intervention showed no clear difference in adverse events leading to discontinuation of therapy (low certainty).
1 finding from 1 review
Treatment discontinuation · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod showed no clear difference in treatment discontinuation compared with cidofovir (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events a. Serious adverse events b. Discontinuation of trial because of adverse events · obese children and adolescents
The intervention showed no clear difference in adverse events a. Serious adverse events b. Discontinuation of trial… (low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · patients with rheumatoid arthritis
Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in discontinuations due to adverse events Analysis 6.3 compared with methotrexate monotherapy (moderate certainty).
1 finding from 1 review
Treatment discontinuation · women with high‐grade VIN
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found